found no significant interaction between any of the SNPs studied and the response to naltrexone treatment. Anton et al. (2008) examined the moderating effect of the Asn40Asp SNP on the response to naltrexone treatment in a sub-sample of 297 EA subjects from the COMBINE Study (Anton et al. 2006). A positive moderating effect on the response to naltrexone was observed for carriers of the Asp40 allele on the percentage of heavy drinking days, with a robust effect on a global measure of treatment outcome. Kim et al. (2009) found a positive moderating effect of the Asp40 allele on time to relapse in a sample of 32 treatment-seeking Korean alcoholics.
